



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, November 07<sup>th</sup>, 2019

To,

The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai-400001.

Dear Sir/Ma'am,

**Sub:** Outcome of Board Meeting – Regulation 30.

**Ref:** Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its Meeting held on Thursday, 07<sup>th</sup> November, 2019 at 3:00 PM, at the corporate office of the Company *inter-alia* the following:

1. Considered and Approved the Un-Audited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2019.
2. Took note of Limited Review Report for the quarter and half year ended 30<sup>th</sup> September, 2019.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,  
for Vista Pharmaceuticals Limited

  
M.H. Rao  
DIRECTOR  
DIN: 00129311





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana  
India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, November 07<sup>th</sup>, 2019

To  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai- 400001.

Dear Sir/Ma'am,

**Sub:** Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2019 – Regulation 33 (3) (a).

**Ref:** Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Thursday, 07<sup>th</sup> November, 2019 at 3.00 P.M. at the Corporate office of the Company, interalia, considered and approved the unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2019.

Copy of un-audited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2019 and Limited review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,  
*for Vista Pharmaceuticals Limited*

  
M.H. Rao  
DIRECTOR  
DIN: 00129311





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

## Statement of Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2019

(in Rs Lakhs)

S.No	Particulars	Quarter ended			Half- Year ended		Year ended
		September 30,2019	June 30,2019	September 30,2018	September 30,2019	September 30,2018	March 31,2019
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
<b>1</b>	<b>Income</b>						
	a. Revenue from operations	809.48	712.35	588.00	1521.83	1187.66	3107.28
	b. Other income	11.82	319.76	62.66	331.58	117.74	294.85
<b>2</b>	<b>Total Income (a+b)</b>	<b>821.30</b>	<b>1032.11</b>	<b>650.66</b>	<b>1853.41</b>	<b>1305.40</b>	<b>3402.13</b>
<b>3</b>	<b>Expenses</b>						
	a) Cost of Material Consumed	661.69	666.19	383.70	1327.87	772.72	2681.07
	b) Change in Inventories	7.33	96.83	-	104.16	-	(139.90)
	c) Employee benefits expense	35.70	36.90	37.17	72.60	67.67	136.26
	d) Finance costs	44.13	41.13	40.71	85.26	84.45	167.39
	e) Depreciation and amortization expense	34.22	32.30	34.59	66.52	67.57	136.40
	f) Other expenses	26.15	148.33	108.17	174.48	228.20	306.21
	<b>Total Expenses</b>	<b>809.21</b>	<b>1,021.67</b>	<b>604.34</b>	<b>1,830.88</b>	<b>1,220.61</b>	<b>3,287.42</b>
<b>4</b>	<b>Profit before tax (2-3)</b>	<b>12.09</b>	<b>10.44</b>	<b>46.32</b>	<b>22.53</b>	<b>84.79</b>	<b>114.71</b>
<b>5</b>	<b>Tax expense</b>						
	(1) Current tax	0.95	3.38	6.76	4.33	17.46	23.62
	(2) Deferred tax	1.06	(2.32)	30.33	(1.26)	47.58	2.84
<b>6</b>	<b>Net Profit for the Period (4-5)</b>	<b>10.07</b>	<b>9.38</b>	<b>9.24</b>	<b>19.45</b>	<b>19.75</b>	<b>93.94</b>
<b>7</b>	<b>Other comprehensive income (OCI)</b>						
	(a) (i) Items that will not be reclassified to profit or loss		-				-
	(ii) Tax on items that will not be reclassified to profit or loss		-	-	-	-	-
	(b) (i) Items that will be reclassified to profit or loss		-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	-	-
	<b>Total Other Comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>8</b>	<b>Total Comprehensive income (6+7)</b>	<b>10.07</b>	<b>9.38</b>	<b>9.24</b>	<b>19.45</b>	<b>19.75</b>	<b>93.94</b>
	<b>Earnings per equity share</b>						
	(Face value of Rs. 10/- each)						
	(1) Basic	0.03	0.03	0.03	0.07	0.07	0.31
	(2) Diluted	0.03	0.03	0.03	0.07	0.07	0.31
	Paid- up equity share capital(Face Value of Rs.2/- each)	607.31	607.31	582.94	607.31	582.94	607.31

### Notes:


1.The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 07.11.2019.

2.The Standalone Financial results for the quarter and half year ended 30th September 2019 are reviewed by the Statutory Auditors of the Company as per Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.

4.These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

5.Figures for the previous periods /year have been regrouped/reclassified wherever necessary.





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana  
India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

**VISTA PHARMACEUTICALS LIMITED**  
**CIN:L24239TG1991PLC012264**  
**STATEMENT OF ASSETS AND LIABILITIES**

Particulars	(Rs. In lakhs)	
	As at 30th September 2019 (Un Audited)	As at 31st March 2019 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	1,178.59	1,245.03
Capital work-in-progress	872.33	854.23
Intangible assets	807.17	807.17
Financial Assets	-	-
Investments	4.14	2.93
Other financial assets	9.65	9.65
Deferred Tax Asset (net)	13.34	12.08
Other Non-Current Assets	-	-
<b>Total Non - Current Assets</b>	<b>2,885.22</b>	<b>2,931.09</b>
<b>Current assets</b>		
Inventories	968.15	1,124.59
<b>Financial assets</b>		
Trade receivables	533.30	834.57
Cash and cash equivalent	90.54	86.77
Other financial assets	-	-
(c) Other current assets	231.93	298.76
<b>Total Current Assets</b>	<b>1,823.92</b>	<b>2,344.70</b>
<b>Total Assets</b>	<b>4,709.14</b>	<b>5,275.79</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share capital	607.31	607.31
Other equity	2,744.08	2,972.77
<b>Total Equity</b>	<b>3,351.39</b>	<b>3,580.08</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	557.52	595.54
Deferred tax liabilities (Net)	-	-
Other non current liabilities	5.15	5.47
<b>Total Non - Current Liabilities</b>	<b>562.67</b>	<b>601.01</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	527.46	520.98
Trade payables	214.46	525.34
Other financial liabilities	5.30	5.30
Other current liabilities	19.92	19.47
Provisions	27.95	23.62
<b>Total Current Liabilities</b>	<b>795.08</b>	<b>1,094.70</b>
<b>Total Liabilities</b>	<b>1,357.75</b>	<b>1,695.71</b>
<b>Total Equity and Liabilities</b>	<b>4,709.14</b>	<b>5,275.79</b>
	(0.00)	(0.00)



**MAHESH, VIRENDER & SRIRAM**

**Chartered Accountants**

6-3-788/36 & 37A, Durganagar Colony, Ameerpet, Hyderabad - 500 016

Phone: 040 - 23401738

E-mail :mvshyd@yahoo.com

**Annex 1 - Exhibit C1: Limited Review Report for listed entities other than banks and insurance companies - unaudited standalone quarterly and year to date results.**

Review report to Board of Directors of **VISTA PHARMACEUTICALS LIMITED.**

We have reviewed the accompanying statement of unaudited Quarterly financial results of Vista Pharmaceuticals Limited for the period ended 30th September 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Conclusion is not modified in respect of this matter.

For Mahesh Virender & Sriram

Chartered Accountants

FR No: 001939S

RV Chalam

Partner

M.No:021423

UDIN:19021423AAAAHU4681



Place of signature: Hyderabad

Date: 06-11-2019